The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
a study on Critical Limb Ischemia
Two phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).
A Randomized Trial Comparing the Drug-Eluting Stent (DES) Below-the-Knee (BTK) Vascular Stent System (DES BTK Vascular Stent System) vs Percutaneous Transluminal Angioplasty (PTA) Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia
Phase A: A global, prospective, multicenter, 2:1 randomized trial evaluating the safety and effectiveness of the DES BTK Vascular Stent System compared to standard percutaneous transluminal angioplasty to treat infrapopliteal artery lesions in subjects with critical limb ischemia(CLI). Phase A RCT will begin with one size of the device: 3.5 mm x 80 mm. Phase B: A global, prospective, multicenter, non-randomized trial collecting additional safety and effectiveness data for the DES BTK Vascular Stent System to treat infrapopliteal artery lesions in subjects with CLI. Additional stent sizes will be added to the trial upon regulatory approval. Approximately 201 subjects will be randomized/enrolled to support a 2:1 randomization in the phase A RCT. Assuming the effectiveness endpoint is met in phase A RCT, approximately 100 additional subjects are expected to be enrolled in phase B non-randomized which is structured as a single arm where the enrolled subjects are treated with the DES BTK Vascular Stent System.
Critical Limb Ischemia Ischemia Drug Eluting Stent - Below the Knee DES BTK
You can join if…
Open to people ages 18 years and up
- Subject is 18 years or older and has signed and dated the trial informed consent form (ICF)
- Subject is willing and able to comply with the trial testing, procedures and follow-up schedule
- Subject has chronic, symptomatic lower limb ischemia, determined by Rutherford categories 4 or 5 in the target limb, with wound(s) confined to toes/forefoot
- Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator
Intra-procedure Inclusion Criteria:
- Stenotic, restenotic or occlusive target lesion(s) located in the tibioperoneal trunk, anterior tibial, posterior tibial and/or peroneal artery(ies).
- Target lesion(s) must be at least 4cm above the ankle joint
- A single target lesion per vessel, in up to 2 vessels, in a single limb
- Degree of stenosis ≥ 70% by visual angiographic assessment
- Reference vessel diameter is between 2.5 - 3.25mm for phase A RCT
- RVD is between 2.5 - 3.75mm for phase B non-randomized (Note: RVD is dependent on stent size being used. Refer to DFU for specific requirements)
- Total target lesion length (or series of lesion segments) to be treated is ≤ 70 mm for phase A RCT prior to the data monitoring committee's approval for stent overlap. (Note: Lesion segment(s) must be fully covered with one DES BTK stent, if randomized to stent)
- Total target lesion length (or series of lesion segments) to be treated is ≤ 140 mm for phase A RCT after the data monitoring committee's approval for stent overlap (Note: Lesion segment(s) must be fully covered with up to two DES BTK stents, if randomized to stent)
- Total target lesion length (or series of lesion segments) to be treated is ≤ 140 mm for phase B non-randomized (Note: Lesion segment(s) must be fully covered with up to two DES BTK stents)
- . Target vessel(s) reconstitute(s) at or above the stenting limit zone (4cm above the ankle joint)
- . Target lesion(s) is located in an area that may be stented without blocking access to patent main branches
- . Treatment of all above the knee inflow lesion(s) is successful prior to treatment of the target lesion
- . Guidewire has successfully crossed the target lesion(s)
You CAN'T join if...
- Life expectancy ≤ 1year
- Stroke ≤ 90 days prior to the procedure date
- Prior or planned major amputation in the target limb
- Previous surgery in the target vessel(s) (including prior ipsilateral crural bypass)
- Previously implanted stent in the target vessel(s)
- Failed PTA of target lesion/vessel ≤ 60 days prior to the procedure date
- Renal failure as measured by a GFR ≤ 30ml/min per 1.73m2, measured ≤ 30 days prior to the procedure date
- Subject has a platelet count ≤ 50 or ≥ 600 X 103/µL ≤ 30 days prior to the procedure date
- NYHA class IV heart failure
- . Subject has symptomatic coronary artery disease (ie, unstable angina)
- . History of myocardial infarction or thrombolysis ≤ 90 days prior to the procedure date
- . Non-atherosclerotic disease resulting in occlusion (eg, embolism, Buerger's disease, vasculitis)
- . Subject is currently taking Canagliflozin
- . Body Mass Index (BMI) <18
- . Active septicemia or bacteremia
- . Coagulation disorder, including hypercoagulability
- . Contraindication to anticoagulation or antiplatelet therapy
- . Known allergies to stent or stent components
- . Known allergy to contrast media that cannot be adequately pre-medicated prior to the interventional procedure
- . Known hypersensitivity to heparin
- . Subject is on a high dose of steroids or is on immunosuppressive therapy
- . Subject is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Boston Scientific study team)
Intra-procedure Exclusion Criteria
- Angiographic evidence of intra-arterial acute/subacute thrombus or presence of atheroembolism
- Treatment required in > 2 target vessels (Note: a target lesion originating in one vessel and extending into another vessel is considered 1 target vessel)
- Treatment requires the use of alternate therapy in the target vessel(s)/lesion(s), (eg, atherectomy, cutting balloon, re-entry devices, laser, radiation therapy)
- Aneurysm is present in the target vessel(s)
- Extremely calcified lesions
- University of California, San Francisco
accepting new patients
San Francisco California 94143 United States
- USC University Hospital
Los Angeles California 90033 United States
Lead Scientist at UCSF
- Michael Conte, M.D.
Professor, Surgery. Authored (or co-authored) 258 research publications.
- accepting new patients
- Start Date
- Completion Date
- Boston Scientific Corporation
- Phase 3
- Study Type
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT03551496.